Khoo Shih
About Khoo Shih
Khoo Shih is the Managing Director at Temasek and the Chief Executive Officer at ClavystBio in Singapore, with extensive experience in life sciences investment and biomedical sciences.
Current Leadership Roles
Khoo Shih serves as the Chief Executive Officer at ClavystBio in Singapore. In addition to his role at ClavystBio, he works as the Managing Director at Temasek. His leadership roles in both organizations highlight his extensive experience and expertise in the life sciences and investment sectors.
Career at ClavystBio
Khoo Shih began his tenure at ClavystBio as a Senior Investment Advisor, a position he held from 2022 to 2023 for 11 months. His rapid transition from this advisory role to Chief Executive Officer underscores his expertise and leadership abilities. At ClavystBio, he is responsible for steering the company's strategic vision and operations.
Professional Experience at Temasek
Khoo Shih has a long-standing career at Temasek, beginning as the Vice President of Life Sciences Investment from 2007 to 2010. He was then promoted to Director, Life Science Investment, a role he held for six years until 2016. Currently, he serves as the Managing Director, continuing to leverage his extensive background in life sciences investment to drive the firm's strategic initiatives.
Educational Background
Khoo Shih has a strong academic foundation in the sciences. He earned a Bachelor of Science in Microbiology from the National University of Singapore. He further advanced his education by obtaining a Doctor of Philosophy (Ph.D.) in Genes & Development from The University of Texas Southwestern Medical School. His educational qualifications provide a solid basis for his extensive career in life sciences and investment management.
Early Career and Experience
Khoo Shih began his professional journey at the Singapore Economic Development Board (EDB) working in the Biomedical Sciences sector from 2000 to 2003. He then moved to UOB Venture Management as an Investment Manager, where he worked for four years until 2007. These roles laid the groundwork for his later positions in life sciences investment and management.